In older women with early stage lung cancer, UCLA’s Jonsson Comprehensive Cancer Center researchers have discovered a novel mechanism to predict their survival.
Higher levels of aromatase (an enzyme that naturally makes estrogen from another hormone called androgen) have, for the first time, been linked to more aggressive disease and lower survival rates in women over 65 with Stage 1 or 2 lung cancer.
Such findings do not only provide possible need tool in predicting survival but also new target for therapy using aromatase inhibitors.
According to the study’s senior author, Lee Goodglick, an associate professor in the UCLA Department of Pathology and …read more

Androgen deprivation therapy (ADT) is one of the most common treatments for prostate cancer.
ADT works by blocking the level of circulating androgens (male hormones) – the ones that can fuel the growth of prostate cancers.
According to a research team from Dana-Farber Cancer Institute, Brigham and Women’s Hospital and other institutions, ADT may increase the risk of death from heart disease mortality in prostate cancer patients above age 65.
Such findings have been reported at the recent Prostate Cancer Symposium- sponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology and the Society of Urologic Oncology …read more